Advice

following a full submission:

rucaparib (Rubraca®) is accepted for use within NHSScotland.

Indication under review: as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

In a phase III study, maintenance treatment with rucaparib significantly improved investigator-assessed progression-free survival, compared with placebo, in patients with advanced ovarian cancer who were in response to first-line platinum-based chemotherapy.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

Medicine details

Medicine name:
rucaparib (Rubraca)
SMC ID:
SMC2799
Indication:

As monotherapy for the maintenance treatment of adult patients with
advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

Pharmaceutical company
pharmaand GmbH (pharma&)
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
08 September 2025